INSTANTPEPTIDES

IGF-1 LR3: Long R3 IGF-1 Analog Research Overview

IGF-1 LR3 (Long R3 IGF-1) is a synthetic modified analog of insulin-like growth factor 1 (IGF-1) with two structural changes: a 13-amino acid N-terminal extension and a substitution at position 3 (arginine replacing glutamate). These modifications reduce binding to IGF-binding proteins (IGFBPs), producing a research tool with altered pharmacokinetic and signaling behavior. This page summarizes the published preclinical literature.

Last reviewed: 2026-05-11· Instant Peptides Research Team
Research-use reference only. The content below summarizes published preclinical and in vitro research. Not for human or animal consumption, diagnostic, or therapeutic use. Information is provided as an educational resource for qualified research professionals.

Background

IGF-1 (insulin-like growth factor 1) is a 70-amino acid polypeptide produced primarily in the liver in response to growth hormone stimulation. Endogenous IGF-1 circulates predominantly bound to a family of six IGF-binding proteins (IGFBPs), which regulate its bioavailability and half-life. Free IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, and activates downstream PI3K/Akt and Ras/MAPK signaling.[1]

IGF-1 LR3 was developed by Francis and colleagues in the early 1990s as a tool for studying IGF biology with reduced IGFBP interference. The Arg3 substitution dramatically reduces binding to IGFBPs while preserving IGF-1R binding, effectively making LR3 a 'free' IGF-1 analog in the bloodstream.[2]

IGF-1 LR3 is studied as a research reference compound. It has not been approved by the FDA for any human therapeutic, diagnostic, or medical purpose.

Chemistry & Structure

IGF-1 LR3 has two engineered modifications relative to native IGF-1:

  • N-terminal extension: 13 additional amino acids (MFPAMPLSSLFVN) added to the N-terminus of mature IGF-1
  • Position 3 substitution: glutamate (Glu) replaced by arginine (Arg)
  • Total length: 83 amino acids (vs 70 for native IGF-1)
  • Molecular weight: approximately 9,200 Da
  • Disulfide bonds: three (preserved from native IGF-1)

Why the modifications matter

The IGFBPs bind IGF-1 in a region that includes the N-terminus and the early residues. The 13-amino acid extension and the Arg3 substitution disrupt this binding interface, reducing IGFBP affinity dramatically (estimates range from 100 to 1000-fold weaker binding).[2][3]

Importantly, the IGF-1R binding interface is on a different face of the molecule. LR3's modifications target IGFBP binding selectively without disrupting receptor engagement, so the analog retains IGF-1R-binding affinity comparable to native IGF-1.

Receptor Pharmacology

IGF-1 LR3's research-characterized activity is at the IGF-1 receptor.

IGF-1R activation

IGF-1R is a receptor tyrosine kinase structurally related to the insulin receptor. Ligand binding induces receptor dimerization, autophosphorylation, and recruitment of IRS-1/IRS-2 signaling adapters that propagate to PI3K/Akt and MAPK pathways.[4]

Reduced IGFBP buffering

Because LR3 doesn't sequester to IGFBPs, the unbound (active) fraction is much higher than for native IGF-1 in identical preparation conditions. This makes LR3 useful for in vitro studies where IGFBP interference would complicate interpretation.[3]

Documented Preclinical Research Areas

IGF-1 LR3 has been used across many preclinical research contexts.

Cell culture studies

Cell culture systems where IGFBPs in serum-containing media would otherwise sequester native IGF-1 are a primary application for LR3. Researchers use the analog to maintain bioavailable IGF-1 receptor signaling in serum-containing cultures.[5]

Myogenesis research

Skeletal muscle cell differentiation and myotube formation assays use IGF-1R signaling as a research endpoint. LR3 is a tool for examining receptor-mediated effects on myogenic differentiation in vitro.[6]

Cancer cell biology research

IGF-1R signaling is implicated in numerous cancer cell biology research questions. LR3 provides a research tool for studying receptor-mediated proliferation and survival pathways in cell lines without IGFBP confounders.[4]

Stability & Handling

IGF-1 LR3 is a relatively large polypeptide with three disulfide bonds, requiring careful handling.

Storage

Lyophilized IGF-1 LR3 is stored at minus 20 degrees Celsius or colder. Repeated freeze-thaw cycles should be avoided. Reconstituted solution is sensitive to repeated freeze-thaw.

Reconstitution

Acetic acid solutions (typically 0.1 percent acetic acid in water) are commonly used to reconstitute IGF-1 LR3, as the slightly acidic conditions help solubilize the peptide. Bacteriostatic water can also be used.

Quality verification

Quality verification includes HPLC for purity, mass spectrometry for identity confirmation matching the 83-amino acid modified sequence, and verification of correct disulfide bond formation by reduced/oxidized peptide mapping. Each batch of Instant Peptides IGF-1 LR3 ships with a full Certificate of Analysis.

Available Research Material

Instant Peptides supplies IGF-1 LR3 as a synthetic lyophilized reference compound. Material is supplied to qualified research professionals. Not for human or animal consumption.

View the product page for current pricing and the Certificate of Analysis for the active batch.

Available Research Material

IGF-1 LR3

Lyophilized synthetic reference compound. Independently tested for purity by HPLC and mass spectrometry. Full Certificate of Analysis included.

View product details

References

  1. 1.LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Letters. 2003. PMID: 12888337
  2. 2.Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I. Journal of Molecular Endocrinology. 1992. PMID: 1378730 (LR3 design paper.)
  3. 3.Bayne ML, Applebaum J, Chicchi GG, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor. Journal of Biological Chemistry. 1988. PMID: 2459132
  4. 4.Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer. 2008. PMID: 19029956
  5. 5.Tomas FM, Knowles SE, Owens PC, et al. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment with an insulin-like growth factor-I analogue, with reduced binding affinity for IGF-binding proteins. Biochemical Journal. 1991. PMID: 1872383
  6. 6.Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocrine Reviews. 1996. PMID: 8854049

Related Research